Nurr1/Foxa2 Gene Composition for Inhibiting Tau Tangle Formation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease, particularly those targeting tau protein accumulation, aggregation, and tangle formation, are inadequate, leading to significant mental anguish and high management costs, with no effective cure available.
Innovation Solution
Introducing Nurr1 and Foxa2 genes, either together or alone, into brain cells using vectors or direct gene introduction methods to inhibit tau protein accumulation, aggregation, and tangle formation, leveraging the synergistic effects of these transcription factors to alleviate pathological symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for Alzheimer's disease, then management and treatment costs are incurred, but the treatments are ineffective in preventing or curing the disease
Solution Approach 1:
The invention changes the fundamental parameter of treatment approach from symptomatic management to gene-based therapeutic intervention. By introducing Nurr1 and Foxa2 genes, the treatment targets the underlying molecular mechanisms of tau protein pathology, transforming ineffective conventional therapy into a potentially curative genetic intervention that addresses the root cause of the disease
Solution Approach 2:
The invention uses gene vectors as intermediaries to deliver therapeutic genetic material into brain cells. These vectors serve as mediators that transport the Nurr1 and/or Foxa2 genes across the blood-brain barrier and into target cells, enabling the genetic intervention to reach its therapeutic destination and exert its disease-modifying effects
2Ease of operation
If no effective treatment is available, then patients suffer from mental anguish, but current therapeutic options remain undeveloped
Solution Approach 1:
The invention employs preliminary protective action by introducing genes that prevent tau protein accumulation and neurodegeneration before irreversible damage occurs. The Nurr1 and Foxa2 genes are delivered to brain cells to establish protective mechanisms that can halt or reverse early pathological processes, preventing the progression to severe cognitive impairment and mental anguish
Solution Approach 2:
The invention converts the harmful accumulation of tau proteins into a beneficial therapeutic opportunity. By targeting the molecular pathways that lead to tau pathology, the genetic intervention transforms the disease process itself into a treatment target, using the understanding of harmful mechanisms to design therapies that specifically counteract those harmful effects
3Reliability
If tau protein accumulation is not inhibited, then neurofibrillary tangles form and disease progresses, but no effective method exists to prevent this process
Solution Approach 1:
The invention extracts and targets the specific molecular culprit - tau protein - from the complex disease process. By focusing the genetic intervention on inhibiting tau accumulation and aggregation, the therapy isolates and addresses the key pathological element responsible for neurofibrillary tangle formation, simplifying the therapeutic approach to targeting a single critical disease mechanism
Solution Approach 2:
The invention uses composite genetic interventions combining Nurr1 and/or Foxa2 genes delivered via vector systems. This composite approach integrates multiple functional elements - the therapeutic genes themselves, the vector delivery system, and the resulting protein expression machinery - to create a multifaceted therapeutic solution that addresses the complexity of neurodegenerative disease through coordinated genetic action
Data Source
AI summary
Disclosed are a composition and method for inhibiting tau protein accumulation, aggregation, or tangle, the composition containing neurons or glia having Nurr1 and/or Foxa2 genes introduced thereinto, wherein the composition and method can be utilized in the prevention or treatment of a cerebral nervous disease caused by tau protein accumulation, aggregation, or tangle formation.